Mofuder (Mometasone Furoate)

Mometasone furoate penetrates skin cells and binds to intracellular glucocorticoid receptors. The resulting complex alters gene transcription, suppressing pro‑inflammatory cytokines and chemokines while increasing anti‑inflammatory proteins. This cascade reduces cellular infiltration, edema and the overall inflammatory response in the skin.

The specific dose and frequency of Mofuder are determined by the prescribing healthcare professional based on the severity of the condition, patient age and the area of skin to be treated. Typically, a thin layer is applied to the affected area once or twice daily for a short period.

Safety data for mometasone furoate in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any possible risk to the fetus, and caution is advised when breastfeeding.

To request Mofuder, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is considered a high‑potency topical corticosteroid, offering stronger anti‑inflammatory effects than low‑ to medium‑potency agents such as hydrocortisone. Compared with other high‑potency steroids, its efficacy is similar, but formulation differences may affect skin feel and absorption, influencing clinician preference.

Mofuder should be stored at room temperature, below 25 °C, in its original container. Keep the product away from direct sunlight, moisture and heat sources. Ensure the cap is tightly closed after each use to maintain stability and potency.

Apply a thin layer of Mofuder to the clean, dry affected skin area, gently rubbing it in until it disappears. Follow the prescriber’s instructions regarding frequency and duration, and avoid covering the treated area with occlusive dressings unless specifically advised.

Serious, though rare, risks include skin atrophy, hypopigmentation and secondary bacterial or fungal infections. Systemic absorption can lead to adrenal suppression or other corticosteroid‑related effects, especially with extensive or prolonged use. Patients should report any unusual skin changes or systemic symptoms promptly.

Mofuder is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided on untreated viral, bacterial or fungal skin infections, and in patients requiring systemic corticosteroid therapy for unrelated conditions without medical supervision.